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Abstract
Despite a population of only 20 million and sustained low prevalence of HIV infection in Australia,
Australian researchers have provided many substan t i a l  o r i g i n a l  f i n d i n g s  t o  t h e  f i e l d s  o f  H I V
pathogenesis, treatment and prevention. More recently, Australian clinicians and scientists have
turned their attention to assisting other countries in developing effective responses, particularly
within the Asia-Pacific region. It is therefore fitting that the 4th International AIDS Society (IAS)
Conference on HIV Pathogenesis, Treatment and Prevention will be held in Sydney in July 2007.
The meeting is expected to attract over 5000 participants and will have a dynamic and innovative
programme within the three major themes of HIV basic science, clinical research and biomedical
prevention.
The HIV epidemic in Australia
Australia is generally viewed as a success story in the glo-
bal HIV epidemic, with its national strategic response in
place since the late 1980s credited with delivering
extremely low infection rates and high levels of treatment
access. Perhaps less well known is the extent to which Aus-
tralia has been able to contribute to the world's knowl-
edge about HIV infection, particularly in the areas of
pathogenesis and clinical medicine. A unique combina-
tion of a geographically and demographically focussed
epidemic, specialised medical units, a history of outstand-
ing research in basic immunology and virology and dedi-
cated national resources for health care and research has
given rise to a scientific output that is disproportionate to
the size of Australia's HIV epidemic.
Although Australia was one of the first countries in the
Asia Pacific Region to report AIDS cases, and its epidemic
curve rose sharply during the first half of the 1980s, it had
begun to plateau by the early 1990s, and reached a peak
even before the treatment revolution was under way. A
rapid expansion of needle and syringe programs ensured
that people who injected illicit drugs were largely pro-
tected from HIV infection, with prevalence consistently
reported as being below 1% in this population. Nation-
ally, the estimated prevalence is now among the lowest in
the world, at around 0.1%
By far the most common cause of HIV transmission has
been male to male sex, which has been associated with
most of the cumulative 22,000 diagnoses estimated to
have occurred in Australia since the first case in 1982. In
the first decade of the epidemic, the proportion was even
higher, and cases of HIV infection were highly concen-
trated in the large urban centres, where vibrant gay com-
munities had developed in the late 1970s. In several cities,
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these communities were located near teaching hospitals
with an established track record in virology and clinical
infectious diseases, such as the Fairfield Infectious Dis-
eases Hospital in Melbourne. At one stage it was estimated
that 60% of the people with HIV infection in Australia
lived in a five km radius of St Vincent's Hospital, Sydney.
In addition, Australia had a proud history of outstanding
scientific research, particularly in the fields of virology and
viral immunology that was well established prior to the
arrival of HIV infection. Notable virologists such as Pro-
fessor Frank Fenner and Professor Ian Gust, together with
Nobel Prize winning immunologists Professor Macfarlane
Burnet and Professor Peter Doherty had already influ-
enced the generations of investigators who subsequently
immersed themselves in HIV research. The national and
State governments in Australia supported both the provi-
sion of services and the conduct of research, and it was
this confluence of circumstances that fostered a dynamic
culture of discovery across the spectrum of scientific disci-
plines involved in investigating HIV infection.
Notable early discoveries
Some key early clinical research discoveries in Australia
included the initial description of HIV seroconversion ill-
ness (an illness similar to the presentation of acute infec-
tious mononucleosis or "glandular fever" which occurs
within days to weeks following infection with HIV) [1];
the identification of HIV transmission by artificial insem-
ination [2]; the transmission of HIV from mother to child
not just during pregnancy but following delivery [3]; the
predictive value of the CD4+ T-cell count in the develop-
ment of particular opportunistic infections and malignan-
cies in HIV-infected individuals [4]; and patient to patient
transmission via inadequate sterilisation of surgical
instruments used in an outpatient setting [5].
In 1992, a group of people in Sydney who had become
infected with HIV following receipt of blood products
from a single donor were identified as showing slow or no
progression to AIDS [6]. The sequence of the virus that
infected both the donor and recipients demonstrated
multiple mutations in the U3 region of LTR overlapping
the nef gene [Deacon, 1995]. The mutations in LTR-nef led
to an attenuated virus that was less pathogenic than wild
type virus. This observation strongly suggested that HIV
Nef was a key viral determinant for disease progression in
humans – a finding that had previously only been shown
in monkeys infected with nef-deleted mutants of SIV. Sub-
sequent work on the virology, immunology, neuropathol-
ogy and clinical outcome of the Sydney blood bank
cohort has led to over 30 publications, several patents and
an ongoing productive research program on the study of
non-progressive HIV infection.
Novel clinical studies
Following the widespread introduction of highly active
antiretroviral therapy (HAART) in 1996, came the first
reports from Sydney of the clinical syndrome of lipodys-
trophy characterised by loss of fat in the periphery (face,
buttocks, arms and legs), deposition of fat centrally
(abdomen, breast and upper back) and associated meta-
bolic disturbances including hypercholesterolemia,
hypertriglyceridemia and insulin resistance [7]. Although,
the mechanism of lipodystrophy was originally elusive,
several Australian groups have identified a number of fac-
tors that contribute to the complex, multifactorial etiol-
ogy of this syndrome. Some of these factors include the
contribution of mitochondrial toxicity to fat wasting and
the association of the lipodystrophy syndrome with spe-
cific classes of antiretroviral agents [8]. More recently,
strategies to potentially reverse or treat these complica-
tions have been explored, although to date an effective
treatment for this syndrome has proven difficult to
develop [9].
Detailed characterisation of a relatively small cohort of
HIV-infected individuals in Perth identified the associa-
tion of hypersensitivity to the HIV reverse transcriptase
inhibitor abacavir and carriage of the HLA-B5701 allele
[10]. As a result of this significant finding, a simple screen-
ing test for this allele is now commonly performed prior
to the use of abacavir. Abacavir is not prescribed to indi-
viduals who carry this allele and therefore screening can
effectively prevent nearly all hypersensitivity reactions to
this drug.
Perth researchers also published one of the first descrip-
tions of potent immune restoration to opportunistic path-
ogens following the initiation of antiretrovirals – even just
following the use of AZT, a relatively weak antiretroviral
agent when used alone [11]. With the subsequent use of
HAART, immune restoration disease (IRD) was then
defined as a very important and common clinical syn-
drome. IRD occurs with a wide range of pathogens and
the pathogenesis and genetic predisposition to develop-
ment of IRD has since been well characterised [12].
HIV basic research
Australia has also generated important basic science find-
ings that have arisen from astute clinical observations and
detailed study of clinical samples. The initial description
of the association between clinical resistance to AZT and a
mutation from leucine to tryptophan at position 210 in
the reverse transcriptase was first reported from Mel-
bourne in 1996 [13]. Australian researchers also made
several key findings regarding the role of macrophages as
a long term reservoir for HIV including in individuals
receiving HAART [14]; the pathogenesis and prevalence of
HIV-related dementia and other neurological complica-Retrovirology 2006, 3:86 http://www.retrovirology.com/content/3/1/86
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tions [15-17] and our understanding of T-cell turnover in
acute and established infection [18,19]. More recently,
came the demonstration that HIV can bind to its co-recep-
tor CCR5, with increasing efficiency at the later stages of
infection, or when an individual progresses to AIDS [20].
This finding may potentially account for increasing path-
ogenicity of viral isolates in AIDS, without the use of alter-
nate co-receptors such as CXCR4.
Investigators in Perth used sophisticated statistical algo-
rithms to identify that polymorphisms in HIV were signif-
icantly associated with particular host HLA class I alleles
and that absence of polymorphism was also HLA allele-
specific [21]. Furthermore, at a population level, the
degree of HLA-associated selection in viral sequence was
predictive of HIV viral load. These results supported a fun-
damental role for HLA-restricted immune responses in
driving and shaping HIV evolution in vivo and led to a sig-
nificant change in thinking of how virus adaptation
occurs.
Basic molecular investigations of HIV replication have
also led to novel findings including a molecular basis for
the role of Tat protein for fully efficient reverse transcrip-
tion [22]; the intrinsic antiviral resistance of the double
stranded (ds)RNA activated PKR system and its role in
restricting HIV replication in astrocytes [23]; and critical
steps in HIV RNA and reverse transcriptase dimerisation,
packaging and virion assembly pathways [24,25].
Several groups in Australia have played a key role in our
understanding of the interaction of HIV with different
dendritic cell subsets [26,27]. Immature, mature and tis-
sue-derived dendritic cells all express a range of receptors
that can bind HIV and that are exclusive to this cell line-
age. These receptors are all part of the c-type lectin family,
are diverse in number and have differing affinity for bind-
ing to HIV [28], a finding that may have implications for
the development of agents to inhibit the binding of HIV
to these receptors and block sexual transmission.
Innovative prevention strategies
Beyond the basic and clinical sciences, Australian
researchers have also been active in epidemiological and
social research related to HIV infection. The effectiveness
of needle and syringe programmes in the prevention of
HIV infection was demonstrated in a comprehensive anal-
ysis of international prevalence data [29]. Insights into
sexual behaviour of gay men have crucially informed pre-
vention strategies both nationally and internationally.
The development of effective biomedical prevention strat-
egies is currently an active and growing area of research in
Australia. Some novel approaches developed in Australia
have included the production and evaluation of a "prime
boost" preventative vaccine (DNA priming with fowlpox
boost) which was shown to be strongly immunogenic in
primates [30]. Although less immunogenic in humans,
the administration and synthesis of these constructs is cur-
rently being optimised and this prime boost vaccine will
be evaluated in phase II human studies in Thailand in the
next year. Another novel strategy recently shown to induce
HIV-specific T-cell responses in primates is the infusion of
small overlapping peptides that match the HIV consensus
sequence together with autologous whole blood [31].
This strategy could potentially be used in humans as a
therapeutic or prophylactic vaccine. Australian based bio-
technology companies have also been active in the devel-
opment of new agents with the potential for use as vaginal
microbicides.
Despite some indications of an upturn in infection rates
over the past few years, the epidemic in this country has
been largely stable, and Australian clinicians and scientists
have increasingly turned their attention to assisting other
countries in developing effective responses. Within the
Asia-Pacific region, Australia has played a key role in the
development of clinical investigation and disease surveil-
lance, though research collaborations in Thailand and
Cambodia, and donor funded bilateral programs in
extremely resource-poor countries such as Myanmar and
more recently Papua New Guinea. The Burnet Institute
based in Melbourne has played a major role in the advo-
cacy, introduction and maintenance of needle syringe
programs throughout the region.
IAS 2007 in Sydney
Given Australia's significant contribution to our under-
standing of HIV pathogenesis and prevention and its
emerging leadership role within the Asia-Pacific region, it
is fitting that the 4th International AIDS Society (IAS)
Conference on HIV Pathogenesis, Treatment and Preven-
tion will be held in Sydney in July 2007 [32]. The IAS
Conference on HIV Pathogenesis, Treatment and Preven-
tion is one of the leading international conferences for
researchers in all scientific fields related to HIV – basic sci-
ence, virology, immunology, epidemiology, clinical man-
agement and pharmacology.
The local host for the conference is the Australasian Soci-
ety for HIV Medicine (ASHM). ASHM is Australasia's peak
body representing the HIV medical and research commu-
nities. The society incorporated in 1990 and was one of
the first National HIV/AIDS societies in the world, and an
early member of the International AIDS Society. It has
successfully run an annual scientific conference on HIV/
AIDS since 1989. This year, over 1000 delegates attended
the 19th ASHM annual conference in Melbourne.Retrovirology 2006, 3:86 http://www.retrovirology.com/content/3/1/86
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This is the first time an HIV-related conference of this
magnitude will be held in Australia. Over 5000 delegates
from over 150 countries are expected to attend. We are
planning an exciting and innovative program that will
highlight cutting edge research in each of the three major
themes of basic science, clinical research and biomedical
prevention. We encourage established researchers, post-
doctoral fellows and graduate students interested in HIV
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